The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Adjuvant and neoadjuvant approaches in early-stage HCC
Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, gives an overview of emerging immunotherapy approaches in earlier stages of hepatocellular carcinoma (HCC). Neoadjuvant therapy has resulted in enhanced response rates, even in resectable cases, and post-resection pathologic complete response may be a predictor of overall survival. The Phase III IMbrave150 trial (NCT03434379) has additionally demonstrated the efficacy of atezolizumab with bevacizumab in the adjuvant setting. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
